IDEXX Laboratories, Inc. IDXX

519.26 5.87 1.14% as of 25 Sep
Market cap
$40.2B
P/E
36.2×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

IDEXX Laboratories, Inc. (IDXX) EV/Sales

As of 25 September 2026, IDEXX Laboratories, Inc. (IDXX) trades at a EV/Sales of 9.1×. Over the past ten years it has ranged from 3.9× (January 2016) to 20.0× (August 2021); the current reading is higher than 37% of that period. That is above the Diagnostics & Research industry median of 5.7× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 12.7× 43.85%
FY2024 8.8× (29.30%)
FY2023 12.5× 21.56%
FY2022 10.3× (41.83%)
FY2021 17.7× 10.73%
FY2020 16.0× 64.11%
FY2019 9.7× 29.33%
FY2018 7.5× 5.83%
FY2017 7.1× 17.26%
FY2016 6.1× 38.47%

Quarterly

Period EV/Sales Change
Jun 2026 9.2× (9.27%)
Mar 2026 10.1× (20.34%)
Dec 2025 12.7× 2.84%
Sep 2025 12.4× 14.71%
42 more quarters

Against its own ten years

Low 3.9× High 20.0×
Ten-year median 10.0×
Current reading's percentile 37

EV/Sales against peers

Company EV/Sales
DGX Quest Diagnostics Incorporated compare 2.7×
IQV IQVIA Holdings Inc. compare 3.5×
A Agilent Technologies, Inc. compare 6.9×
MTD Mettler-Toledo International, Inc. compare 7.9×
IDXX IDEXX Laboratories, Inc. 9.1×
ILMN Illumina, Inc. compare 9.3×
WAT Waters Corporation compare 10.1×
GH Guardant Health, Inc. compare 20.3×
NTRA Natera, Inc. compare 21.6×
Diagnostics & Research industry median 5.7×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on IDXX